There is no one-size-fits-all approach to treating chronic disease. Every patient and their disease is different and they will respond to treatment in their own unique way. Our team of multi-disciplinary scientists combine groundbreaking research with best-in-class technology to develop targeted therapies to improve patient outcomes.
The field of advanced therapy medicinal products (ATMPs) has enormous potential to fulfil previously unmet medical needs. Our scientists are working to translate this potential into reality with a range of ATMPs to effectively treat a range of chronic diseases, including cancer.
Dendritic cell (DC) vaccination is a form of immunotherapy. During this therapy DCs are activated in vitro against specific peptides and then administered back to the same patient in order to activate both CD8+ and CD4+ cells against these specific peptides. DendroCov has been developed to recognise specific peptides of SARS-CoV-2, resulting in the activation of both humoral and cell-mediated immunity. DendroCov is a personalised therapy and therefore results in no side-effects for the patient. Our chosen peptides are not within the mutated parts of the virus, so it gives protection against mutated SARS-CoV-2 strains known so far. DendroCov has been approved by the CAT committee of the EMA as an CTMP (Cell Therapeutic Medicinal Product).
Supportive Oligonucletide Therapy (SOT)
SOT is a personalised therapy for cancer, viruses and pathogens including Lyme Disease. The SOT has the ability to bind to a specific gene of interest that controls the cancer cell or pathogen by disrupting the critical process that promotes its survival or growth. During this therapy, we analyse a patient’s blood and we create a complementary oligonucleotide sequence that is designed to interrupt survival or growth of the cells. RGCC SOTs are available to RGCC Network doctors. Please contact us to discuss your requirements.
Vaxo-Q-Re is a new advanced therapy consisting of five types of immune cells; macrophages, NK cells, dendritic cells, cytotoxic T lymphocytes and antibody producing plasma cells. Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Vaxo-Q-Re has been in development by RGCC scientists for more than five years and is now categorised as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA). It is due to enter clinical trials shortly.
To find out more about our range of ATMPs, please contact firstname.lastname@example.org.